LABP — Landos Biopharma Share News
0.000.00%
Last trade - 00:00Brief: Landos Biopharma Provides Business Update And Reports First Quarter 2023 Results
Landos Biopharma Inc expected to post a loss of 9 cents a share - Earnings Preview
Landos Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Landos Biopharma Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Landos Biopharma Inc Maintains Cash Balance Of Low Single Digit Millions With SVB
Brief: Landos Biopharma Announces Transfer Of Lancl Portfolio, Including Omilancor, Labp-104 And Labp-111 To Landos’ Founder
Brief: Landos Biopharma Announces Acceptance Of Abstract On Ulcerative Colitis Study
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
Brief: Landos Biopharma Announces $16.7 Mln Private Placement Financing
Brief: Landos Biopharma Provides Comprehensive Update On Clinical Development Plans
Brief: Nasdaq Approves Landos Biopharma's Application To Transfer To Nasdaq Capital Market
Landos Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Landos Biopharma Reports Third Quarter Results
Brief: Landos Biopharma Announces Appointment Of Fabio Cataldi, MD, As Chief Medical Officer
U.S. RESEARCH ROUNDUP-Goodrx Holdings, Nextnav, Olo
Brief: Landos Biopharma Reports Q2 2022 Results
Brief: Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1B Trial
Landos Biopharma Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Landos Biopharma Says Tim Mayleben, Who Has Been Serving As Interim President And CEO Since Nov 2021, Will Continue To Serve As Member Of Company's Board